Genentech's Independence Deal: A Victory for Biotech Companies

Genentech's successful negotiation to maintain its independence from Roche has sent shockwaves through the biotechnology industry. Analysts and experts are hailing the move as a victory for biotech companies, which have long battled to maintain their entrepreneurial spirit in the face of increasing pressure from big pharmaceutical groups. The deal has been seen as a significant coup for Genentech's management, who had threatened to leave if the company became a subsidiary of Roche.

Key Takeaways:

• Genentech's management had threatened to leave if the company became a subsidiary of Roche, citing concerns over the loss of its entrepreneurial spirit.
• Biotechnology companies are often run by fiercely independent researchers who are loath to work in bureaucratic pharmaceutical behemoths.
• The biotechnology industry has struggled to maintain independence, with many companies becoming dependent on partnerships with pharmaceuticals to finance their research.
• The most successful biotechnology groups have struggled to maintain any independence, with companies like Immunex and Chiron Corporation being majority-owned by pharmaceutical companies.
• Genentech's success in maintaining separate operations is a rare exception, with other biotech companies struggling to achieve similar success.
• Analysts believe that Genentech's record of bringing products to market is a key factor in its ability to stay independent.
• The deal is likely to have a positive impact on Genentech's stock price, which has been suffering due to concerns over its future pipeline of products.

Statistics:

• 50% of Immunex is owned by American Home Products.
• Novartis owns almost half of Chiron Corporation.
• Genentech is one of only two fully independent biotechnology companies, along with Genzyme.
• Genentech has a successful track record of bringing products to market, with analysts attributing its success to its independence.

Sources:

• Financial Times Limited [1999]. "Genentech's management refuses to yield on corporate independence."